S
Sheldon M. Cooper
Researcher at University of Vermont
Publications - 47
Citations - 3885
Sheldon M. Cooper is an academic researcher from University of Vermont. The author has contributed to research in topics: Rheumatoid arthritis & Arthritis. The author has an hindex of 22, co-authored 41 publications receiving 3726 citations. Previous affiliations of Sheldon M. Cooper include National Institutes of Health & University of Massachusetts Medical School.
Papers
More filters
Journal ArticleDOI
Germline mutations in the extracellular domains of the 55 kda tnf receptor, tnfr1, define a family of dominantly inherited autoinflammatory syndromes
Michael F. McDermott,Ivona Aksentijevich,Jérôme Galon,Elizabeth M. McDermott,B. William Ogunkolade,Michael Centola,Elizabeth Mansfield,Massimo Gadina,Leena Karenko,Tom Pettersson,John McCarthy,David M. Frucht,Martin Aringer,Yelizaveta Torosyan,Anna-Maija Teppo,Meredith Wilson,H.Mehmet Karaarslan,Ying Wan,Ian Todd,Geryl Wood,Ryan Schlimgen,Thisum R. Kumarajeewa,Sheldon M. Cooper,John P. Vella,Christopher I. Amos,John C. Mulley,Kathleen A. Quane,Michael G. Molloy,Annamari Ranki,Richard J. Powell,Graham A. Hitman,John J. O'Shea,Daniel L. Kastner +32 more
TL;DR: It is proposed that the autoinflammatory phenotype results from impaired downregulation of membrane TNFR1 and diminished shedding of potentially antagonistic soluble receptor inTNFR1-associated periodic syndromes.
Journal ArticleDOI
Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4.
TL;DR: Results suggest a prominent role for L3T4+ T cells in the pathogenesis of CIA and administration of monoclonal anti-L3T 4 before immunization with type II collagen resulted in a significant decrease in arthritis incidence and delayed onset of the disease.
Journal ArticleDOI
Minocycline in rheumatoid arthritis : a 48-week, double-blind, placebo-controlled trial
Barbara C. Tilley,Graciela S. Alarcón,Stephen P. Heyse,David E. Trentham,Rosemarie Neuner,David L. Kaplan,Daniel O. Clegg,James C. C. Leisen,Lenore M. Buckley,Sheldon M. Cooper,Howard Duncan,Stanley R. Pillemer,Marilyn Tuttleman,Sarah Fowler +13 more
TL;DR: A 48-week, randomized, double-blind, multicenter trial to determine the efficacy and safety of minocycline in treating rheumatoid arthritis when it is added to background NSAIDs or low-dose prednisone therapy in patients not receiving concomitant disease-modifying antirheumatic drugs.
Journal ArticleDOI
Calcium and Vitamin D3 Supplementation Prevents Bone Loss in the Spine Secondary to Low-Dose Corticosteroids in Patients with Rheumatoid Arthritis: A Randomized, Double-Blind, Placebo-Controlled Trial
TL;DR: In this paper, the effects of supplemental calcium and vitamin D 3 on bone mineral density of patients with rheumatoid arthritis and the relation between the effect of this supplementation and corticosteroid use were assessed.
Journal Article
Calcium and Vitamin D3 Supplementation Prevents Bone Loss in the Spine Secondary to Low-Dose Corticosteroids in Patients with Rheumatoid Arthritis
TL;DR: It was found that calcium and vitamin D3 prevented substantial loss of bone mineral density in a similar group of patients starting corticosteroid treatment.